Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 +0.30 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
Why Did Truist Lower IGM Biosciences' Price Target?
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Why Is IGM Biosciences (IGMS) Stock Up Today?
Here are the various catalysts investors in IGM Biosciences and IGMS stock are watching today as shares more than double. 
Via InvestorPlace
Mid-Afternoon Market Update: Dow Surges 250 Points; NeoGenomics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow jumping over 250 points on Tuesday. 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide... 
Via Benzinga
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 2.5%; IGM Biosciences Shares Jump
U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday. 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: IGMS) shares jumped 49.8% to $22.46. Sanofi SA (... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; McCormick Profit Beats Estimates
U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning. 
Via Benzinga
IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi
Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against  
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY). Guardforce AI Co.,... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers
Pre-open movers 
Via Benzinga
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
Regeneron-Sanofi's Dupixent Significantly Improved Signs, Symptoms In Chronic Itchy Skin Disease
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) have presented  
Via Benzinga
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection. 
Via Benzinga
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA... 
Via Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases. 
Via Benzinga
Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Up to 60,000 people in the US with a rare genetic kidney... 
Via Benzinga
Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren& 
Via Benzinga
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
From Seagen Inc.
Via Business Wire
Why Sanofi Shares Are Trading Lower Today
Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in... 
Via Benzinga
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474
JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says... 
Via Benzinga
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001)... 
Via Benzinga
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116... 
Via Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.